VC-backed Phreesia files to go public


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




New York-based Phreesia, a healthcare software company, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The company plans on trading the stock on the New York Stock Exchange under the ticker symbol “PHR.” J.P. Morgan, Wells Fargo Securities and William Blair are the lead underwriters. Phreesia’s backers include LLR Partners, HLM Venture Partners, Polaris Partners, Ascension Ventures, Echo Health Venture and Blue Cross Blue Shield Venture Partners.

PRESS RELEASE

NEW YORK, June 24, 2019 /PRNewswire/ — Phreesia announced it has publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of shares of its common stock.

The number of shares to be offered and the price range for the proposed offering have not yet been determined. The

Continue reading “VC-backed Phreesia files to go public”

VC-backed Akero Therapeutics debuts IPO


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Akero Therapeutics Inc, a biotech firm, has raised about $92 million for its IPO after pricing its 5.75 million shares at $16 per share. The stock began trading June 20, 2019 on the NASDAQ under the ticker symbol “AKRO.” J.P. Morgan Securities LLC, Jefferies LLC and Evercore Group L.L.C. are the lead underwriters. Akero’s pre-IPO investors included Janus Henderson Investors, Redmile Group, Boxer Capital of Tavistock Group, Cormorant Asset Management, BVF Partners, Rock Springs Capital, LifeSci Venture Partners, Apple Tree Partners, Atlas Venture, venBio Partners and Versant Ventures.

PRESS RELEASE

SAN FRANCISCO, June 19, 2019 /PRNewswire/ — Akero Therapeutics, Inc. (NASDAQ: AKRO), a clinical-stage biotechnology company developing transformational treatments for people with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced the pricing of its initial public offering of 5,750,000 shares of common stock at a public offering price of $16.00 per

Continue reading “VC-backed Akero Therapeutics debuts IPO”

Prevail Therapeutics begins trading on NASDAQ


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




New York City-based Prevail Therapeutics, a gene therapy company, has gone public after pricing its over 7.3 million shares at $17 per share. The stock began trading June 20, 2019 on the NASDAQ under the ticker symbol “PRVL.” Morgan Stanley, BofA Merrill Lynch and Cowen are the lead underwriters. Prevail’s pre-IPO backers included OrbiMed, Pontifax Fund, RA Capital Management, EcoR1 Capital, Omega Funds, BVF Partners LP, Boxer Capital LLC, Adage Capital Management LP and Alexandria Venture Investments.

PRESS RELEASE

NEW YORK–(BUSINESS WIRE)–Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today announced the pricing of its initial public offering of 7,353,000 shares of its common stock at a price to the public of $17.00 per share. In addition, Prevail has granted the underwriters a 30-day option to purchase up to an additional 1,102,950 shares of

Continue reading “Prevail Therapeutics begins trading on NASDAQ”

VC-backed Personalis unveils IPO


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Personalis Inc, a provider of advanced genomics solutions for cancer, has debuted its IPO after pricing its nearly 8 million shares at $17 per share. The stock began trading June 20, 2019 on the NASDAQ under the ticker symbol “PSNL.” Morgan Stanley, BofA Merrill Lynch and Cowen are the lead underwriters. Personalis’ pre-IPO backers included Lightspeed Venture Partners, Abingworth and Mohr Davidow Ventures.

PRESS RELEASE

MENLO PARK, Calif.–(BUSINESS WIRE)–
Personalis, Inc., a leader in advanced genomics for cancer, today announced the pricing of its initial public offering of 7,921,500 shares of common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Personalis. In addition, Personalis has granted the underwriters a 30-day option to purchase up to an additional 1,188,225 shares of common stock from Personalis at the public offering price less underwriting

™

Continue reading “VC-backed Personalis unveils IPO”

Biopharma firm Atreca goes public


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Redwood City, California-based Atreca Inc, a biopharmaceutical company, has raised about $113.8 million for its IPO after pricing its 7.35 million shares at $17 per share. The stock began trading June 20, 2019 on the NASDAQ under the ticker symbol “BCEL.” Cowen, Evercore ISI and Stifel are the lead underwriters. Atreca’s pre-IPO backers included Wellington Management Company LLC, Cormorant Asset Management, Aisling Capital, Boxer Capital of the Tavistock Group, EcoR1 Capital, Redmile Group, Samsara BioCapital and funds managed by Tekla Capital Management.

PRESS RELEASE

REDWOOD CITY, Calif., June 19, 2019 (GLOBE NEWSWIRE) — Atreca, Inc. (Nasdaq: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, today announced the pricing of its initial public offering of 7,350,000 shares of common stock at a price to the public of $17.00 per share.

Continue reading “Biopharma firm Atreca goes public”

VC-backed Fiverr goes public


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Fiverr International, an online marketplace for freelancers, has debuted its IPO after raising over 5.2 million shares at $21 per share. The stock began trading June 13, 2019 on the New York Stock Exchange under the ticker symbol “FVRR.” J.P. Morgan Securities LLC and Citigroup Global Markets Inc are the lead underwriters. Fiverr’s pre-IPO backers included Square Peg Capital, Bessemer Venture Partners, Accel and Qumra Capital.

PRESS RELEASE

NEW YORK–(BUSINESS WIRE)–
Fiverr International Ltd. (“Fiverr”), announced today the pricing of its initial public offering of 5,263,158 ordinary shares at a public offering price of $21.00 per share. The underwriters of the offering will also have a 30-day option to purchase up to an additional 789,473 ordinary shares from Fiverr at the initial public offering price. The shares are expected to begin trading on the New York Stock Exchange on June 13, 2019 under the ticker

Continue reading “VC-backed Fiverr goes public”

Warburg-backed ESR Cayman delays Hong Kong listing: Bloomberg


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




ESR Cayman, a logistics real estate developer, has postponed its Hong Kong listing due to unfavorable market conditions, reported Bloomberg. ESR and some of its shareholders. ESR had planned on raising as much as $1.24 billion for the listing. ESR is backed by Warburg Pincus.

PE-backed CrowdStrike debuts IPO


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




CrowdStrike, a cybersecurity firm, has debuted its IPO after pricing its 18 million shares at $34 per share. The stock began trading June 12, 2019 on the NASDAQ under the ticker symbol “CRWD.” Goldman Sachs, J.P. Morgan, BofA Merrill Lynch and Barclays are the lead underwriters. CrowdStrike’s pre-IPO backers included Warburg Pincus, General Atlantic, Accel, IVP, CapitalG and March Capital.

PRESS RELEASE

Sunnyvale, CA – June 11, 2019 – CrowdStrike Holdings, Inc. (Nasdaq: CRWD), today announced the pricing of its initial public offering of 18,000,000 shares of its Class A common stock at a price to the public of $34.00 per share. CrowdStrike has granted the underwriters a 30-day option to purchase up to 2,700,000 additional shares of Class A common stock at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market

Continue reading “PE-backed CrowdStrike debuts IPO”

PE-backed CrowdStrike debuts IPO


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




CrowdStrike, a cybersecurity firm, has debuted its IPO after pricing its 18 million shares at $34 per share. The stock began trading June 12, 2019 on the NASDAQ under the ticker symbol “CRWD.” Goldman Sachs, J.P. Morgan, BofA Merrill Lynch and Barclays are the lead underwriters. CrowdStrike’s pre-IPO backers included Warburg Pincus, General Atlantic, Accel, IVP, CapitalG and March Capital.

PRESS RELEASE

Sunnyvale, CA – June 11, 2019 – CrowdStrike Holdings, Inc. (Nasdaq: CRWD), today announced the pricing of its initial public offering of 18,000,000 shares of its Class A common stock at a price to the public of $34.00 per share. CrowdStrike has granted the underwriters a 30-day option to purchase up to 2,700,000 additional shares of Class A common stock at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market

Continue reading “PE-backed CrowdStrike debuts IPO”

PE-backed Grocery Outlet sets IPO pricing terms


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Emeryville, California-based Grocery Outlet, a retailer of consumables and fresh products, has set its IPO pricing terms between $15 and $17 per share. The stock will trade on the NASDAQ under the ticker symbol “GO.” The lead underwriters are BofA Merrill Lynch, Morgan Stanley, Deutsche Bank Securities, Jefferies, Barclays, Goldman Sachs & Co. LLC, Guggenheim Securities, UBS Investment Bank and Cowen. Grocery Outlet is a portfolio company of Hellman & Friedman.

PRESS RELEASE

EMERYVILLE, Calif., June 10, 2019 (GLOBE NEWSWIRE) — Grocery Outlet Holding Corp. (“Grocery Outlet”) today announced the launch of its initial public offering of 17,187,500 shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission. The initial public offering price is expected to be between $15.00 and $17.00 per share. Grocery Outlet has applied to have its common stock approved for listing on The Nasdaq

Continue reading “PE-backed Grocery Outlet sets IPO pricing terms”

Emerging markets online fashion retailer GFG prepares listing: Reuters


This post is by Reuters News from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Global Fashion Group (GFG), an Asia and Latin America focused online retailer which has yet to make a profit, is preparing to list shares in Frankfurt to raise funds for further growth, the company said on Monday.

Online fashion retail has grown rapidly in the last decade, particularly in developed economies with strong logistics networks. However, it has proven tougher to turn a profit in places where parcel delivery can be unreliable.

Swedish investor Kinnevik, which owns 35% of the company, valued GFG at 1 billion euros in March, or 0.7 times the company’s 2018 revenues. That compares to a range of 1.1-2.7 times for Western-focused peers such as Zalando, ASOS , Boohoo and Stitch Fix.

GFG, which is also 20% owned by German start-up incubator Rocket Internet and operates The Iconic, Zalora, Dafiti and Lamoda platforms, said it was planning to raise about 300 million euros

Continue reading “Emerging markets online fashion retailer GFG prepares listing: Reuters”

Luxury online reseller The RealReal files for IPO: Reuters


This post is by Reuters News from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




U.S. online luxury reseller The RealReal Inc on Friday filed for an initial public offering with the U.S. securities regulator.

The company intends to list on the Nasdaq under the symbol “REAL”, a filing with the U.S. Securities and Exchange Commission showed.

Earlier in January, Reuters reported the company’s plans to go public later this year, citing sources familiar with matter.

The company set a placeholder amount of $100 million to indicate the size of the IPO.

The size in preliminary filings is used to calculate registration fees and the final amount could be different.

The RealReal, which specializes in online secondhand luxury apparel and goods, was valued at $745 million in a funding round in July last year, according to data provider PitchBook.

Founded in 2011, The RealReal’s success is built on a profitable mix of the boom in e-commerce, and a younger clientele’s interest in

Continue reading “Luxury online reseller The RealReal files for IPO: Reuters”

PE-backed Cambium files to go public


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Cambium, a provider of wireless broadband networking infrastructure solutions, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The company plans on trading its stock on the NASDAQ under the ticker symbol “CMBM.” J.P. Morgan Securities LLC and Goldman Sachs will serve as lead underwriters. Cambium is a portfolio company of Vector Capital.

PRESS RELEASE

ROLLING MEADOWS, IL, May 30, 2019 — Cambium Networks Corporation (“Cambium”), a provider of wireless broadband networking infrastructure solutions, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares. The number of ordinary shares to be offered and the price range for the proposed offering have not yet been determined. Cambium intends to list its

Continue reading “PE-backed Cambium files to go public”

European drug wholesaler Abacus postpones IPO: Reuters


This post is by Reuters News from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Danish drug merchant Abacus Medicine, which buys medicines in cheaper parts of the European Union to sell them in more expensive markets like Germany, on Wednesday said it is postponing its planned initial public offering due to an “unfavorable market environment.”

Abacus, which makes the bulk of its sales in Germany, had said earlier this month it was reviving plans to sell its shipoares in a public offering. Last week, it had set its IPO price range as 14.50 euros ($16.15) to 16.00 euros per share.

The company said it is monitoring the market environment without specifying when it would go for an IPO.

China’s Hansoh Pharma secures GIC, Boyu Capital among investors for up to $1 billion HK IPO: Reuters


This post is by Reuters News from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




Chinese drugmaker Hansoh Pharmaceutical Group has secured nine cornerstone investors including Singapore’s GIC and China’s Boyu Capital for its up to $1 billion Hong Kong initial public offering (IPO), according to a term sheet seen by Reuters.

The Jiangsu-based drugmaker started book-building of its Hong Kong float on Thursday, in what would be the city’s second-largest IPO so far this year. It is selling about 551 million primary shares, or 9.7% of its enlarged share capital, at an indicative range of HK$13.06 to HK$14.26 ($1.66 to $1.82), the term sheet showed.

Hansoh has lined up a total of $344 million from nine cornerstone investors based on the top-end of the price range. Singapore’s sovereign wealth fund GIC Pte Ltd has made the biggest commitment of $70 million, followed by private equity firm Boyu, which is pledging $60 million, according to the term sheet.

Other cornerstones

Continue reading “China’s Hansoh Pharma secures GIC, Boyu Capital among investors for up to $1 billion HK IPO: Reuters”

VC-backed Bicycle Therapeutics goes public


This post is by Iris Dorbian from PE Hub Blog: PE-Backed IPOs


Click here to view on the original site: Original Post




UK-based Bicycle Therapeutics, a biopharmaceutical firm, has raised about $60.7 million for its IPO after pricing its over 4.3 million shares at $14 per share. The stock began trading May 23, 2019 on the NASDAQ under the ticker symbol “BCYC.” Goldman Sachs, Jefferies LLC and Piper Jaffray & Co are the lead underwriters. Bicycle Therapeutics’ pre-IPO backers included Vertex Ventures HC, Cambridge Innovation Capital, Longwood Fund, Novartis Venture Fund, SROne, SVLS and Atlas Venture.

PRESS RELEASE

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced the pricing of its initial public offering in the United States of 4,333,333 American Depositary Shares (“ADSs”) representing 4,333,333 ordinary shares at an initial public offering price of $14.00 per ADS, before underwriting discounts and commissions. In addition, Bicycle has

Continue reading “VC-backed Bicycle Therapeutics goes public”